HYDERABAD, Apr 4: Dr Reddy’s Laboratories today announced the launch of Zoledronic Acid Injection (5 mg/100 mL), a therapeutic equivalent generic version of Reclast, in the US market following an approval by the United States Food & Drug Administration (USFDA).
A company release here said ‘Reclast’ had total sales of approximately USD 355 million in the US for the most recent 12 months ending February 2013, according to IMS Health.
Dr Reddy’s Zoledronic Acid Injection (5 mg/100 mL) is available in a single use vial for Intravenous Infusion. (UNI)
Trending Now
E-Paper
Follow our WhatsApp channel